14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RAPT vs BHVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Biohaven Ltd. (BHVN) on higher Unified Composite conviction (52.4/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 4–2 (led by Profitability & Quality), while BHVN wins 3–1 across the 6-pillar growth and valuation breakdown. RAPT trades at $58.02 (N/M Forward P/E, 0.0% operating margin) versus BHVN at $13.95 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. BHVN 42.1/100 HOLD) and -0.02β · 2% Vol risk profile, whereas BHVN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs BHVN. Trailing 12-month operating profitability (RAPT 0.0% vs BHVN 0.0%) and valuation multiples (RAPT N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RAPT vs BHVN Key Questions & Quantitative Answers
As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Biohaven Ltd. (BHVN) on higher Unified Composite conviction (52.4/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 4–2 (led by Profitability & Quality), while BHVN wins 3–1 across the 6-pillar growth and valuation breakdown. RAPT trades at $58.02 (N/M Forward P/E, 0.0% operating margin) versus BHVN at $13.95 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. BHVN 42.1/100 HOLD) and -0.02β · 2% Vol risk profile, whereas BHVN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BHVN leads the Growth & Scale pillar: RAPT posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RAPT generates N/A in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, RAPT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.
RAPT and BHVN trade at balanced relative valuation multiples. RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPT (-85.4% ROE) versus BHVN (-799.5% ROE) capital efficiency.
In options market volatility and institutional positioning, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.40β · 111% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.